Sexual dimorphism in solid and hematological malignancies
Standard
Sexual dimorphism in solid and hematological malignancies. / Ben-Batalla, Isabel; Vargas-Delgado, María Elena; Meier, Lara; Loges, Sonja.
in: SEMIN IMMUNOPATHOL, Jahrgang 41, Nr. 2, 01.03.2019, S. 251-263.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Sexual dimorphism in solid and hematological malignancies
AU - Ben-Batalla, Isabel
AU - Vargas-Delgado, María Elena
AU - Meier, Lara
AU - Loges, Sonja
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Cancer represents a leading cause of death with continuously increasing incidence worldwide. Many solid cancer types in non-reproductive organs are significantly more frequent and deadly in males compared to females. This sex-biased difference is also present in hematologic malignancies. In this review, we present an overview about sex differences in cancer with a focus on leukemia. We discuss mechanisms potentially underlying the observed sex-biased imbalance in cancer incidence and outcome including sex hormones, sex chromosomes, and immune responses. Besides affecting the pathobiology of cancers, sex differences can also influence drug responses, most notably those to immune checkpoint blockers. Therefore, sex should become a relevant factor in clinical trial design in order to avoid over- or under-treatment of one sex.
AB - Cancer represents a leading cause of death with continuously increasing incidence worldwide. Many solid cancer types in non-reproductive organs are significantly more frequent and deadly in males compared to females. This sex-biased difference is also present in hematologic malignancies. In this review, we present an overview about sex differences in cancer with a focus on leukemia. We discuss mechanisms potentially underlying the observed sex-biased imbalance in cancer incidence and outcome including sex hormones, sex chromosomes, and immune responses. Besides affecting the pathobiology of cancers, sex differences can also influence drug responses, most notably those to immune checkpoint blockers. Therefore, sex should become a relevant factor in clinical trial design in order to avoid over- or under-treatment of one sex.
KW - Journal Article
KW - Review
U2 - 10.1007/s00281-018-0724-7
DO - 10.1007/s00281-018-0724-7
M3 - SCORING: Review article
C2 - 30361802
VL - 41
SP - 251
EP - 263
JO - SEMIN IMMUNOPATHOL
JF - SEMIN IMMUNOPATHOL
SN - 1863-2297
IS - 2
ER -